RxDoctor Payments Data

Matthew Stier, MD

Internal Medicine · Chicago, ILNPI 1902244791

Payments from drug & device makers

$1,870in general payments, 2019–2025

Across 33 payments — averaging $56.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Medical LLC$915
  • AbbVie$315
  • Fujifilm Healthcare Americas Corporation$134
  • Medtronic$125
  • Boston Scientific$95
  • Johnson & Johnson$81
  • plus $206 from 10 others

What the payments were for

  • Grants$80043%
  • Food & beverage$93650%
  • Gifts$794%
  • Other$543%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,870 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$240,848
Medicare patients
422
Services billed
9,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$359,135
RezdiffraResmetirom14$55,570
Mesalamine20$15,122
LinzessLinaclotide21$13,427
Dexlansoprazole DrDexlansoprazole17$7,307
Ursodiol12$3,775
Pantoprazole Sodium163$1,902
Omeprazole184$1,818
Sucralfate11$1,375
Esomeprazole Magnesium27$1,242
Lubiprostone11$1,058
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine17$616
Azathioprine16$406
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl25$329
Dicyclomine Hcl31$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$81$359,13513 claims
AbbVieLinzess$315$13,42721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →